Form 4: Atea Pharmaceuticals Director Arthur S. Kirsch Acquires Stock Options

Director Arthur S. Kirsch of Atea Pharmaceuticals acquired stock options on February 20, 2025.

Summary

• Arthur S. Kirsch, a director of Atea Pharmaceuticals, acquired stock options on February 20, 2025.
• The options grant the right to buy 164,800 shares of common stock at an exercise price of $3.14.
• The options vest in 36 equal monthly installments starting February 20, 2025, and will be fully vested by February 20, 2028.
• The expiration date for the options is February 19, 2035.
• Following the transaction, Kirsch directly owns 164,800 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports an insider transaction. The acquisition of options could be seen as a slightly positive sign, but it's a routine event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

There is no specific future outlook provided in this document beyond the vesting schedule of the options.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.

Key Dates

Keywords

stock options, director, Atea Pharmaceuticals, AVIR, beneficial ownership, Form 4, Kirsch, acquisition